 CytoDyn Inc has announced that Brazils regulatory authority Agência Nacional de Vigilância Sanitária ANVISA has approved its previously submitted clinical trial protocol for its flagship drug candidate leronlimab to start patient enrollment in the CD17 trial for severe coronavirus COVID-19 patients. The Vancouver, Washington-based late-stage biotechnology company said the academic research organization ARO Albert Einstein Israelite Hospital AEIH, in Brazil will conduct the trial. 